ResMed Inc. (RMD): Price and Financial Metrics

ResMed Inc. (RMD): $215.44

-1.53 (-0.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RMD Price/Volume Stats

Current price $215.44 52-week high $247.65
Prev. close $216.97 52-week low $194.30
Day low $214.79 Volume 698,700
Day high $218.44 Avg. volume 595,124
50-day MA $223.73 Dividend yield 0.81%
200-day MA $221.34 Market Cap 31.65B

RMD Stock Price Chart Interactive Chart >

RMD POWR Grades

  • Sentiment is the dimension where RMD ranks best; there it ranks ahead of 90.07% of US stocks.
  • RMD's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • RMD's current lowest rank is in the Momentum metric (where it is better than 15.05% of US stocks).

RMD Stock Summary

  • RMD has a higher market value than 93.07% of US stocks; more precisely, its current market capitalization is $32,383,517,464.
  • Price to trailing twelve month operating cash flow for RMD is currently 60.49, higher than 93.8% of US stocks with positive operating cash flow.
  • The volatility of RESMED INC's share price is greater than that of merely 0.52% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RESMED INC are A, HOLX, TEL, HZNP, and HPE.
  • RMD's SEC filings can be seen here. And to visit RESMED INC's official web site, go to www.resmed.com.

RMD Valuation Summary

  • In comparison to the median Healthcare stock, RMD's price/earnings ratio is 57.26% higher, now standing at 37.9.
  • RMD's price/sales ratio has moved up 2.9 over the prior 243 months.

Below are key valuation metrics over time for RMD.

Stock Date P/S P/B P/E EV/EBIT
RMD 2023-05-23 8.1 8.3 37.9 31.1
RMD 2023-05-22 8.2 8.4 38.4 31.4
RMD 2023-05-19 8.2 8.4 38.2 31.3
RMD 2023-05-18 8.2 8.4 38.2 31.3
RMD 2023-05-17 8.2 8.4 38.1 31.3
RMD 2023-05-16 8.4 8.5 38.9 31.9

RMD Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 53.62%.
  • The 4 year price growth rate now stands at 133.96%.
  • Its year over year cash and equivalents growth rate is now at -12.52%.
Over the past 52 months, RMD's revenue has gone up $1,358,459,000.

The table below shows RMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,763.275 370.223 809.465
2022-09-30 3,624.405 461.466 786.302
2022-06-30 3,578.127 351.147 779.437
2022-03-31 3,539.492 498.186 779.476
2021-12-31 3,443.759 577.025 521.983
2021-09-30 3,348.896 527.062 499.746

RMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMD has a Quality Grade of C, ranking ahead of 68.39% of graded US stocks.
  • RMD's asset turnover comes in at 0.72 -- ranking 50th of 186 Medical Equipment stocks.
  • PEYE, MMSI, and SIEN are the stocks whose asset turnover ratios are most correlated with RMD.

The table below shows RMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.720 0.569 0.426
2021-06-30 0.691 0.575 0.410
2021-03-31 0.673 0.582 0.379
2020-12-31 0.676 0.582 0.342
2020-09-30 0.670 0.583 0.321
2020-06-30 0.672 0.581 0.300

RMD Price Target

For more insight on analysts targets of RMD, see our RMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $261.67 Average Broker Recommendation 1.91 (Hold)

ResMed Inc. (RMD) Company Bio


ResMed is a San DiegoCalifornia-based medical device company. It primarily provides cloud-connectable CPAP devices and masks for the treatment of sleep apnea, as well as devices and masks for treating chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other respiratory-related conditions. It also provides a self-monitoring digital sensor and app for people who use inhalers to treat COPD or asthma via Propeller Health, which ResMed acquired in 2019. (Source:Wikipedia)  


RMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RMD Latest Social Stream


Loading social stream, please wait...

View Full RMD Social Stream

Latest RMD News From Around the Web

Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.

Billionaire Ken Griffin’s 2023 Portfolio: Top 15 Stock Picks

In this piece, we will take a look at the top fifteen stocks in billionaire Ken Griffin’s 2023 portfolio. For more stocks, head on over to Billionaire Ken Griffin’s 2023 Portfolio: Top 5 Stock Picks. The stock market crash of 2022 hammered several major hedge funds. One of the biggest funds that bled capital last […]

Yahoo | May 22, 2023

ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 74% of the company

Key Insights Given the large stake in the stock by institutions, ResMed's stock price might be vulnerable to their...

Yahoo | May 17, 2023

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Yahoo | May 3, 2023

ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer

Rider and Haake, both internal promotions, joined ResMed’s executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as

Yahoo | May 2, 2023

Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge

Growth stock and sleep-apnea device maker ResMed broke out Friday after quarterly earnings continued to accelerate. Shares surged above an entry at 227.94 from a cup with handle in strong volume and are in a buy zone, according to IBD MarketSmith.

Yahoo | May 1, 2023

Read More 'RMD' Stories Here

RMD Price Returns

1-mo -10.42%
3-mo 1.87%
6-mo -3.10%
1-year 4.24%
3-year 38.76%
5-year 123.34%
YTD 3.91%
2022 -19.47%
2021 23.41%
2020 38.33%
2019 37.85%
2018 36.38%

RMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6959 seconds.